Form 4: ANI Pharmaceuticals SVP Chad Gassert Sells 20,000 Shares

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock at a weighted average price of $63.44 on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock on July 1, 2024.
• The sale was executed at a weighted average price of $63.44 per share.
• The shares were sold in multiple trades with prices ranging from $62.81 to $64.11.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on December 12, 2023.
• Following the transaction, Gassert directly owns 49,679 shares and indirectly owns 193,226 shares through Chali Properties LLC.
• Gassert holds voting and dispositive power over the shares held by Chali Properties LLC.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale. It doesn't inherently convey positive or negative sentiment.

Industry Context

This is a routine disclosure of an insider stock sale. It's common for executives to have pre-arranged trading plans to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates